Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
663
datasets available to search
ShareScore release 0.9.0
Dataset results
663 results for “tumor targeting”
Decoding NY-ESO-1 TCR T Cells: Transcriptomic Insights Reveal Dual Mechanisms of Tumor Targeting in a Melanoma Murine Xenograft Model
<p><span>Single-cell RNA-seq data of NY-ESO-1-specific TCR T-cells generated with the BD Rhapsody™ system.</span></p> <p><span>Biogroup information: Control (<em>n</em><span> </span>= 4), PB (murine peripheral blood, <em>n</em><span> </span>= 4).</span></p> <p><span>Cell preparation: NY-ESO-1-specific TCR T-cells were obtained via a retroviral transduction of an anti-NY-ESO-1-TCR construct, murine peripheral blood T-cells were enriched using anti-CD3 magnetic separation via MojoSortTM Human CD3 Selection Kit.</span></p> <p><span>Single-cell analysis system: BD Rhapsody™</span></p> <p><span>Library strategy: 3' mRNA sequencing</span></p> <p><span>Library preparation protocol: BD Rhapsody™ Targeted mRNA and Sample Tag Library Preparation</span></p> <p><span>mRNA panel: BD Rhapsody™ Immune Response Panel HS</span></p> <p><span>BD Pipeline version: 1.11L</span></p>
Pan-cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics
<p>CPTAC PAN-cancer Data Repository</p> <p>Welcome to the CPTAC PAN-cancer Data Repository! This repository serves as a data repository for the CPTAC PAN-cancer effort, which focuses on cancer target discovery. It contains various data sets related to protein abundance estimation, derived TMT-TPA, iBAQ, iBAQ-derived copy number, and differential protein expression for CPTAC ten indications.</p> <p>## Contents</p> <p>The repository includes the following data:</p> <p>- FragPipe Output: Protein abundance estimation data generated using the FragPipe software.<br> - Derived TMT-TPA: Data derived from Tandem Mass Tag (TMT) based Total Protein Approach (TPA).<br> - iBAQ: Data representing intensity-based absolute quantification (iBAQ) of proteins.<br> - iBAQ-derived Copy Number: Data derived from iBAQ analysis for copy number estimation.<br> - Differential Protein Expression: Data indicating differential expression of proteins between tumor and NAT.</p> <p>## Data Organization</p> <p>The data in this repository is organized in a structured manner to facilitate easy access and navigation. The repository structure is as follows:</p> <p>FragPipe/<br> [fragpipe_data_files]<br> Derived_TMT_TPA/<br> [derived_tmt_tpa_data_files]<br> iBAQ/<br> [ibaq_data_files]<br> iBAQ-derived_copy_number/<br> [ibaq_copy_number_data_files]<br> Differential_protein_expression/<br> [differential_expression_data_files]</p>
Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing
<h2>Dataset</h2> <p>Space ranger output (Visium platform) of two human slice culture samples (S1 & S2) injected with GBstarter cells (<span><span>Tetzlaff et al., 2024</span></span>). </p>
Cancer Vaccine Targeting Brachyury Protein in Tumors
ClinicalTrials.gov study NCT01519817. IPD Sharing: NO. Countries: 1. Publications: 5.
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
ClinicalTrials.gov study NCT03760081. IPD Sharing: NO. Countries: 1. Publications: 1.
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced o
ClinicalTrials.gov study NCT00923247. IPD Sharing: NO. Countries: 1. Publications: 4.
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
ClinicalTrials.gov study NCT04034238. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
ClinicalTrials.gov study NCT04632992. IPD Sharing: YES. Countries: 1. Publications: 1.
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
ClinicalTrials.gov study NCT01827384. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cyto
ClinicalTrials.gov study NCT02315625. IPD Sharing: NO. Countries: 1. Publications: 6.
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
ClinicalTrials.gov study NCT00939523. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Scre
ClinicalTrials.gov study NCT03155620. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Data from: D quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies
Quantitative characterization of the in vivo effects of vascular-targeted therapies on tumor vessels is hampered by the absence of useful 3D vascular network descriptors aside from microvessel density. In this study, we extended the quantification of planar vessel distribution to the analysis of vascular volumes by studying the effects of antiangiogenic (sorafenib and sunitinib) or antivascular (combretastatin A4 phosphate) treatments on the quantity and spatial distributions of thin microvessels. These observations were restricted to perinecrotic areas of treated human multiple myeloma tumors xenografted in immunodeficient mice and to microvessels with an approximate cross-sectional area lower than 75 µm2. Finally, vessel skeletonization minimized artifacts due to possible differential wall staining and allowed a comparison of the various treatment effects. Antiangiogenic drug treatment reduced the number of vessels of every caliber (at least 2-fold fewer vessels vs. controls; p<0.001, n = 8) and caused a heterogeneous distribution of the remaining vessels. In contrast, the effects of combretastatin A4 phosphate mainly appeared to be restricted to a homogeneous reduction in the number of thin microvessels (not more than 2-fold less vs. controls; p<0.001, n = 8) with marginal effects on spatial distribution. Unexpectedly, these results also highlighted a strict relationship between microvessel quantity, distribution and cross-sectional area. Treatment-specific changes in the curves describing this relationship were consistent with the effects ascribed to the different drugs. This finding suggests that our results can highlight differences among vascular-targeted therapies, providing hints on the processes underlying sample vascularization together with the detailed characterization of a pathological vascular tree.
Non-coding regions are the main source of targetable tumor-specific antigens - DATASETS (k=24)
<p>Tumor-specific antigens (TSAs) represent ideal targets for cancer immunotherapy, but few have been identified thus far. We therefore developed a proteogenomic approach to enable the high-throughput discovery of TSAs coded by potentially all genomic regions. In two murine cancer cell lines and seven human primary tumors, we identified a total of 40 TSAs, about 90% of which derived from allegedly non-coding regions and would have been missed by standard exome-based approaches. Moreover, the majority of these TSAs derived from non-mutated yet aberrantly expressed transcripts (such as endogenous retroelements) that could be shared by multiple tumor types. In mice, the efficacy of TSA vaccination was influenced by two parameters that can be estimated in humans and could serve for TSA prioritization in clinical studies: TSA expression and the frequency of TSA-responsive T cells in the pre-immune repertoire. In conclusion, the strategy reported herein could considerably facilitate the identification and prioritization of actionable human TSAs.</p>
Non-coding regions are the main source of targetable tumor-specific antigens – DATASETS (k=33)
<p>Tumor-specific antigens (TSAs) represent ideal targets for cancer immunotherapy, but few have been identified thus far. We therefore developed a proteogenomic approach to enable the high-throughput discovery of TSAs coded by potentially all genomic regions. In two murine cancer cell lines and seven human primary tumors, we identified a total of 40 TSAs, about 90% of which derived from allegedly non-coding regions and would have been missed by standard exome-based approaches. Moreover, the majority of these TSAs derived from non-mutated yet aberrantly expressed transcripts (such as endogenous retroelements) that could be shared by multiple tumor types. In mice, the efficacy of TSA vaccination was influenced by two parameters that can be estimated in humans and could serve for TSA prioritization in clinical studies: TSA expression and the frequency of TSA-responsive T cells in the pre-immune repertoire. In conclusion, the strategy reported herein could considerably facilitate the identification and prioritization of actionable human TSAs.</p>
Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9
<p>These files include raw image data from our study titled "Small extrachromosomal circular DNA containing targeted tumor suppressor mutations supports intratumoral heterogeneity in multiplex CRISPR/Cas9-induced mouse liver cancer".</p>
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Br
ClinicalTrials.gov study NCT03006172. IPD Sharing: NO. Countries: 5. Publications: 1.
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective,
ClinicalTrials.gov study NCT07187284. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
ClinicalTrials.gov study NCT04684459. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trop2-targeted immunoPET Imaging of Solid Tumors
ClinicalTrials.gov study NCT06851663. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.